Winther-Larsen, A., Fledelius, J., Demuth, C., Bylov, C. M., Meldgaard, P., & Sorensen, B. S. (2016). Early Change in FDG-PET Signal and Plasma Cell-Free DNA Level Predicts Erlotinib Response in EGFR Wild-Type NSCLC Patients(). Transl Oncol.

Winther-Larsen, Anne, Joan Fledelius, Christina Demuth, Catharina M. Bylov, Peter Meldgaard, and Boe S. Sorensen. "Early Change in FDG-PET Signal and Plasma Cell-Free DNA Level Predicts Erlotinib Response in EGFR Wild-Type NSCLC Patients()." Transl Oncol 2016.

Winther-Larsen, Anne, et al. "Early Change in FDG-PET Signal and Plasma Cell-Free DNA Level Predicts Erlotinib Response in EGFR Wild-Type NSCLC Patients()." Transl Oncol 2016.